Holen Sie sich die Stockscreener-App
4.00
1.23%
-0.05
Lifecore Biomedical Inc Aktie (LFCR) Neueste Nachrichten
LFCR: Barrington Research Maintains Outperform Rating with $5.50 Price Target | LFCR Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Connect - ACCESS Newswire
Lifecore Biomedical signs third site transfer deal in five months By Investing.com - Investing.com Australia
Lifecore Biomedical Signs Commercial Manufacturing Services Agreement with Medical Aesthetics Company - marketscreener.com
Lifecore Biomedical signs third site transfer deal in five months - Investing.com
Lifecore wins deal to help boost U.S. supply of approved aesthetic product - Stock Titan
Published on: 2026-03-23 12:54:24 - baoquankhu1.vn
Lifecore stock sinks as delayed launches push growth further out - MSN
2026-03-22 | Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities Investigation | NDAQ:LFCR | Press Release - Stockhouse
Aug Summary: Is Lifecore Biomedical Inc a strong candidate for buy and holdEarnings Overview Summary & Weekly Stock Performance Updates - baoquankhu1.vn
Rally Mode: Is Lifecore Biomedical Inc a top pick in the sector2026 Analyst Calls & High Accuracy Investment Signals - baoquankhu1.vn
Lifecore Biomedical CEO: Standalone CDMO Shift Complete, Utilization to Hit 60% by 2029 - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Lifecore Biomedical (LFCR) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect - ACCESS Newswire
Lifecore Biomedical at KeyBanc Forum: Strategic Transformation Insights By Investing.com - Investing.com Canada
Lifecore Biomedical at KeyBanc Forum: Strategic Transformation Insights - Investing.com
Lifecore Biomedical (NASDAQ:LFCR) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
Lifecore Biomedical (NASDAQ:LFCR) Upgraded to Outperform at Barrington Research - MarketBeat
Why Is Lifecore Stock Sinking Tuesday?Lifecore Biomedical (NASDAQ:LFCR) - Benzinga
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Craig-Hallum Sticks to Its Buy Rating for Lifecore Biomedical (LFCR) - The Globe and Mail
Lifecore Stock Sinks As Delayed Launches Push Growth Further Out - Sahm
Green Dot Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewswire Inc.
Lifecore Biomedical (LFCR) Q4 Loss Narrows To US$2 Million Reinforcing Bullish Margin Narratives - simplywall.st
Lifecore Biomedical earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Lifecore Biomedical Shareholders Are Encouraged to Reach - GlobeNewswire
Lifecore Biomedical Targets 12% Revenue CAGR and 25%+ EBITDA Margin by 2029 with CDMO Growth Strategy - Minichart
Lifecore Biomedical, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:LFCR) 2026-03-16 - Seeking Alpha
Rate Cut: What is the implied volatility of Lifecore Biomedical Inc2026 Final Week & AI Enhanced Execution Alerts - baoquankhu1.vn
Lifecore Biomedical Transition period Earnings Call Transcript - MarketBeat
Lifecore Biomedical Expands CDMO Capabilities with New Aseptic Filler and Strategic Growth Initiatives - Minichart
Lifecore Biomedical, Inc. Reports Earnings Results for the Fourth Quarter and Seven Months Ended December 31, 2025 - marketscreener.com
Lifecore Biomedical Q4 Earnings Call Highlights - MarketBeat
Lifecore Biomedical’s Competitive Edge in Specialized Sterile Injectables Strengthens Pricing Leverage as Recovery Reduces EBITDA Deficit - Bitget
Lifecore Biomedical reports financial results for the fourth quarter and transition period ended December 31, 2025, and provides corporate update - marketscreener.com
LFCR: Transition period saw 20% revenue growth and improved margins; strong mid-term outlook - TradingView
Lifecore Biomedical Reports Financial Results For The Fourth Quarter And Transition Period Ended December 31, 2025, And Provides Corporate Update - TradingView
Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update - The Manila Times
Lifecore Biomedical: Q4 Earnings Snapshot - marketscreener.com
Lifecore (NASDAQ: LFCR) lifts margins but guides 2026 revenue below 2025 - Stock Titan
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
LFCR Earnings History & Surprises | EPS & Revenue Results | LIFECORE BIOMEDICAL INC (NASDAQ:LFCR) - ChartMill
Lifecore Biomedical (NASDAQ:LFCR) Stock Price Down 2.9%Here's Why - MarketBeat
Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum - The Manila Times
Stream Lifecore Biomedical’s KeyBanc healthcare fireside chat on Mar. 17 - Stock Titan
Lifecore Biomedical, Inc. to Announce Q4 and Transition Period Financial Results on March 16, 2026 - Quiver Quantitative
Lifecore Biomedical to Report Financial Results for the - GlobeNewswire
Lifecore to post Q4 and transition-period earnings on March 16 - Stock Titan
Ideas Watch: Is Lifecore Biomedical Inc forming bullish engulfing patternsLayoff News & AI Driven Stock Price Forecasts - baoquankhu1.vn
Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment - Sahm
Lifecore Sets 2026 Annual Meeting, Proposal Deadlines - TipRanks
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Lifecore to manufacture acne treatment batches for Indomo - Investing.com Nigeria
Lifecore to manufacture acne treatment batches for Indomo By Investing.com - Investing.com Australia
Indomo Partners with Lifecore to Advance At-Home Acne Treatment Using ClearPen™ Device - Quiver Quantitative
Lifecore Biomedical signs new agreement with Indomo to support innovative drug/device combination acne treatment - marketscreener.com
Lifecore Biomedical Signs New Agreement with Indomo to - GlobeNewswire
1.75%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):